100 likes | 213 Views
The SICTO Study CYPHER TM S i rolimus-eluting stent in C hronic T otal O cclusion. Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD. SICTO. STUDY DESIGN
E N D
The SICTO StudyCYPHERTMSirolimus-eluting stentinChronicTotalOcclusion Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD
SICTO STUDY DESIGN A multicenter, prospective, non-randomized study to assess the feasibility and restenosis/reocclusion rates of coronary stenting with the CypherTM Sirolimus-eluting stent in patients with chronic total occlusion • 25 patients were treated with the CypherTM Sirolimus-eluting stent after successful balloon angioplasty and IVUS examination. • Clinical follow-up at 30 days, 6, 12, 18 and 24 months • - repeat angiography and IVUS at 6 months follow-up.
SICTO - Baseline Angiographic & IVUS Data * IVUS estimate (N = 18),**QCA (N=25)
SICTO - Events to 6 months * 1 patient proximal +distal stenosis outside stent 1 patient distal dissection at index procedure,treated at follow-up
Case from SICTO Study • Main complaint: severe shortness of breath and chest pain on mild exertion, increasing over last 6 months • Risk factors: Hyperlipidemia (10 y), DM (25y), HTN • 66 year-old female • Coronary angiography revealed diffusely diseased extremely small coronary arteries with a proximal occlusion in the LAD (arrow)
Case fromSICTO Study Postprocedure 6 mos. follow-up Baseline • Patient underwent successful recanalization of the LAD with implantation of 2 long Cypher stents(2.5/23). • Patient’s condition improved significantly after procedure and returned to functional Class I. • Despite very long lesion (2 stents) in a very diffuse small artery, 6 months follow-up shows stents are widely patent. Chaim Lotan MD Hadassah-Hebrew University Medical Center, Jerusalem Israel
In this feasibility study the CYPHERTM Sirolimus-eluting stent was very effective in the treatment of CTO, with verylow rates of TLR (0%), MACE (0%) and TVR (8%)compared to historical data with bare stents (30-50%). The CYPHERTM Sirolimus-eluting stent significantly inhibits intimal hyperplasia in CTO. These preliminary data will come in addition of larger database with CTO subpopulation (e.g. e-Cypher) SICTO– Conclusion